{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:59:25Z","timestamp":1781704765706,"version":"3.54.5"},"reference-count":15,"publisher":"Norwegian Medical Association","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.18.0967","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T09:16:56Z","timestamp":1569489416000},"source":"Crossref","is-referenced-by-count":0,"title":["Atypisk optikusnevritt"],"prefix":"10.4045","volume":"139","author":[{"given":"Solveig E.J.","family":"Dalbro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Kerty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"ref=1","unstructured":"Wilhelm\u00a0H, Schabet\u00a0M. The diagnosis and treatment of optic neuritis. Dtsch Arztebl Int 2015; 112: 616\u201325, quiz 626. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26396053&dopt=Abstract"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727\u201332. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18541792&dopt=Abstract","DOI":"10.1001\/archneur.65.6.727"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Toosy\u00a0AT, Mason\u00a0DF, Miller\u00a0DH. Optic neuritis. Lancet Neurol 2014; 13: 83\u201399. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24331795&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1474-4422(13)70259-X","DOI":"10.1016\/S1474-4422(13)70259-X"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Bruscolini\u00a0A, Sacchetti\u00a0M, La Cava\u00a0M et al. Diagnosis and management of neuromyelitis optica spectrum disorders - An update. Autoimmun Rev 2018; 17: 195\u2013200. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29339316&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.autrev.2018.01.001","DOI":"10.1016\/j.autrev.2018.01.001"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Wingerchuk\u00a0DM, Banwell\u00a0B, Bennett\u00a0JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177\u201389. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26092914&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1212%2FWNL.0000000000001729","DOI":"10.1212\/WNL.0000000000001729"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Wynford-Thomas\u00a0R, Jacob\u00a0A, Tomassini\u00a0V. Neurological update: MOG antibody disease. J Neurol 2019; 266: 1280\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30569382&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00415-018-9122-2","DOI":"10.1007\/s00415-018-9122-2"},{"key":"ref=7","unstructured":"Gaier\u00a0ED, Boudreault\u00a0K, Rizzo\u00a0JF et al. Atypical optic neuritis. Curr Neurol Neurosci Rep 2015; 15: 76. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26467052&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs11910-015-0598-1"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Duignan\u00a0S, Wright\u00a0S, Rossor\u00a0T et al. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 2018; 60: 958\u201362. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29468668&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fdmcn.13703","DOI":"10.1111\/dmcn.13703"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Petzold\u00a0A, Plant\u00a0GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2014; 261: 17\u201326. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23700317&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00415-013-6957-4","DOI":"10.1007\/s00415-013-6957-4"},{"key":"ref=10","unstructured":"Lee\u00a0HJ, Kim\u00a0B, Waters\u00a0P et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation 2018; 15: 302. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30382857&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2Fs12974-018-1335-x"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Romeo\u00a0AR, Segal\u00a0BM. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol 2019; 31: 250\u20135. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30920972&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FBOR.0000000000000603","DOI":"10.1097\/BOR.0000000000000603"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Bonnan\u00a0M, Valentino\u00a0R, Debeugny\u00a0S et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018; 89: 346\u201351. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29030418&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fjnnp-2017-316286","DOI":"10.1136\/jnnp-2017-316286"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Abboud\u00a0H, Petrak\u00a0A, Mealy\u00a0M et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler 2016; 22: 185\u201392. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25921047&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F1352458515581438","DOI":"10.1177\/1352458515581438"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Cabre\u00a0P, Mejdoubi\u00a0M, Jeannin\u00a0S et al. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol 2018; 265: 917\u201325. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29455361&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00415-018-8771-5","DOI":"10.1007\/s00415-018-8771-5"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Nikoo\u00a0Z, Badihian\u00a0S, Shaygannejad\u00a0V et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017; 264: 2003\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28831548&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00415-017-8590-0","DOI":"10.1007\/s00415-017-8590-0"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:37:12Z","timestamp":1781703432000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2019\/09\/klinisk-oversikt\/atypisk-optikusnevritt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":15,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2019,9,24]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.18.0967","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,23]]}}}